Immunogenicity and Safety of Yellow Fever Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients After Withdrawal of Immunosuppressive Therapy.

Autor:	Sicre de Fontbrune F; Service d'Hématologie Greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP)., Arnaud C; Service de Pédiatrie, Centre Hospitalier Intercommunal de Créteil., Cheminant M; Service d'Hématologie Clinique, Université Paris Descartes-Sorbonne Paris Cité, Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP., Boulay A; INSERM U941, Service de Microbiologie, Hôpital Saint-Louis, AP-HP, Paris., Konopacki J; Service d'Hématologie Clinique, Hôpital d'Instruction des Armées, Clamart., Lapusan S; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, Université Pierre et Marie Curie, Paris., Robin C; Service d'Hématologie, Hôpital Henri Mondor, AP-HP, Université Paris Est, Créteil., Bernaudin F; Service de Pédiatrie, Centre Hospitalier Intercommunal de Créteil., Suarez F; Service d'Hématologie Clinique, Université Paris Descartes-Sorbonne Paris Cité, Institut Imagine, Hôpital Necker-Enfants Malades, AP-HP., Simon F; INSERM U941, Service de Microbiologie, Hôpital Saint-Louis, AP-HP, Paris., Socié G; Service d'Hématologie Greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP)., Colin de Verdière N; Service de Maladies Infectieuses, Hôpital Saint-Louis, AP-HP., Consigny PH; Institut Pasteur, Centre Médical, Centre d'Infectiologie Necker-Pasteur, Paris, France.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2018 Jan 17; Vol. 217 (3), pp. 494-497.
DOI:	10.1093/infdis/jix564
Abstrakt:	As a live attenuated vaccine, yellow fever vaccine (YFV) is not routinely performed after allogeneic hematopoietic stem cell transplant (HSCT) despite it being the only efficient preventive therapy. We retrospectively identified 21 HSCT recipients immunized with YFV at a median of 39 months after HSCT and a median of 33 months after withdrawal of immunosuppression without any side effects. Eighteen evaluable patients had protective immunity after YFV. We also observed that a third of the recipients vaccinated with YFV before HSCT had persistent protective immunity after HSCT. (© The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu